Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGT1A1-Guided Irinotecan in LARC
NCT05148767Phase 4Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan in rectal cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Complete Remission Rate at 3 months, Locally Recurrence Rate at 5 years and 3 more. Started Jan 2022; status: recruiting.
02
Drugs
irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05148767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148767.